dpp 4 inhibitors vs glp 1 agonist Comparison of GLP-1 receptor agonists and DPP-4 DPP-4 inhibitors and GLP-1RAs: cardiovascular
Description
Osibogun, O., Ogunmoroti, O
The global GLP-1 Weight Loss Drug Market was valued at USD 68.65 billion in 2026 and is projected to reach USD 195.01 billion by 2035 , growing at a CAGR of 12.3% during the 20262035 forecast period
J.SchirmerL.et al (2017)
The FDA has classified osteoarthritis as a serious disease with no disease-modifying treatments available
